Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylchitopentaose SCHEMBL20390680 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL619917 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL19427436 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL974524 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL619918 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL13040980 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| SCHEMBL20390674 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL13046690 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL21067311 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL7269765 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 989 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168024-B2 | Use of functionalised chitosan in the treatment of inflammatory/fibrotic pathologies of the respiratory tract and hepatic pathologies | GLYCOCORE PHARMA (IT) | 2024-12-17 | — | — | US | claimed |
| WO-2024239234-A1 | ELECTROCHEMICAL TEST PAPER STABILIZER AND USE THEREOF | 迈克生物股份有限公司 | 2024-11-28 | — | — | WO | claimed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| US-20240254323-A1 | MIXTURES OF POLYSACCHARIDES AND POLYAMINOSACCHARIDES WITH IMPROVED RHEOLOGICAL PROPERTIES | JOINTHERAPEUTICS S.R.L. (IT) | 2024-08-01 | — | — | US | claimed |
| US-20240100084-A1 | USE OF FUNCTIONALISED CHITOSAN IN THE TREATMENT OF INFLAMMATORY/FIBROTIC PATHOLOGIES OF THE RESPIRATORY TRACT AND HEPATIC PATHOLOGIES | GLYCOCORE PHARMA SRL (IT) | 2024-03-28 | — | — | US | claimed |
| EP-4341303-A1 | MIXTURES OF POLYSACCHARIDES AND POLYAMINOSACCHARIDES WITH IMPROVED RHEOLOGICAL PROPERTIES | Jointherapeutics S.r.l. (IT) | 2024-03-27 | — | — | EP | claimed |
| EP-4326283-A1 | USE OF FUNCTIONALISED CHITOSAN IN THE TREATMENT OF INFLAMMATORY/FIBROTIC PATHOLOGIES OF THE RESPIRATORY TRACT AND HEPATIC PATHOLOGIES | GLYCOCORE PHARMA S.r.l. (IT) | 2024-02-28 | — | — | EP | claimed |
| CN-115872668-B | Composite retarding polycarboxylate superplasticizer and preparation method thereof | 科之杰新材料集团有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114807094-B | Chitosan SvChiAJ54 and encoding gene and application thereof | 中国海洋大学 | 2023-11-28 | — | — | CN | claimed |
| CN-113906055-B | Crosslinked polymers of functionalized hyaluronic acid and their use in the treatment of inflammatory states | 卓英医疗有限责任公司 | 2023-09-26 | — | — | CN | claimed |
| US-20020022601-A1 | Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain | JDC (HAWAII) INC., A CORPORATION OF HAWAII | 2002-02-21 | — | — | US | claimed |
| US-6329531-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | SCHERING AG (DE) | 2001-12-11 | — | — | US | claimed |
| US-6252027-B1 | THERMOPLASTIC SUGAR POLYMER | CANON KABUSHIKI KAISHA (JP) | 2001-06-26 | — | — | US | claimed |
| EP-0987284-A1 | Thermally formed article, production process of thermally formed article, toner cartridge and recording medium | CANON KABUSHIKI KAISHA (JP) | 2000-03-22 | — | — | EP | claimed |
| EP-0814093-A2 | Polymeric compound comprising glycopolymer and a method for decomposing the same | CANON KABUSHIKI KAISHA (JP) | 1997-12-29 | — | — | EP | claimed |
| EP-0293931-B1 | Use of an alkaline phosphatase derivative as standard | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-13 | — | — | EP | claimed |
| WO-1990012886-A1 | FLUORESCENT AQUATIC BIOASSAY AND PROCEDURE | HAYES KENNETH R (US) | 1990-11-01 | — | — | WO | claimed |
| US-4895838-A | Method for provoking angiogenesis by administration of angiogenically active oligosaccharides | TRUSTEES OF BOSTON UNIVERSITY (US) | 1990-01-23 | — | — | US | claimed |
| EP-0293931-A2 | Use of an alkaline phosphatase derivative as standard | Roche Diagnostics GmbH (DE) | 1988-12-07 | — | — | EP | claimed |
| EP-0183556-A2 | Use of chitin- or chitosan-oligomers for the manufacture of a immunopotentiating agent for enhancing the immune response against bacterial and fungal infections and against the growth of tumours | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1986-06-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | CD69 1157/4885LGALS3 391/4885LGALS8 634/4885 |
| US-20020022601-A1 | Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain | CHIA, CHIT1, FUT6 | CD69 271/4885LGALS3 636/4885LGALS8 352/4885 |
| US-12168024-B2 | Use of functionalised chitosan in the treatment of inflammatory/fibrotic pathologies of the respiratory tract and hepatic pathologies | LGALS3, LGALS1, LGALS2 | CD69 439/4885LGALS3 1/4885LGALS8 7/4885 |
| US-20240100084-A1 | USE OF FUNCTIONALISED CHITOSAN IN THE TREATMENT OF INFLAMMATORY/FIBROTIC PATHOLOGIES OF THE RESPIRATORY TRACT AND HEPATIC PATHOLOGIES | LGALS3, LGALS1, LGALS2 | CD69 439/4885LGALS3 1/4885LGALS8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.